105P Targeting the tRNA methyltransferase METTL1 with small molecule inhibitors in cancer

Autor: Sapetschnig, A., Thomas, B., Yankova, E., Fischl, H., Azevedo, A., Bucknell, S., Fosbeary, R., Sawyer, S., Evans, S., Livi, C., Andrews, B., Rogan, J., Webster, N., Fyfe, M., Tzelepis, K., Rausch, O.

Publikováno v: In ESMO Open February 2024 9 Supplement 1

Inhibition of METTL3 Results in a Cell-Intrinsic Interferon Response That Enhances Antitumor Immunity.

Autor: Guirguis AA; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia.; Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Victoria, Australia., Ofir-Rosenfeld Y; Storm Therapeutics Ltd, Cambridge, United Kingdom., Knezevic K; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Blackaby W; Storm Therapeutics Ltd, Cambridge, United Kingdom., Hardick D; Storm Therapeutics Ltd, Cambridge, United Kingdom., Chan YC; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia., Motazedian A; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia., Gillespie A; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Vassiliadis D; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia., Lam EYN; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia., Tran K; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia., Andrews B; Storm Therapeutics Ltd, Cambridge, United Kingdom., Harbour ME; Storm Therapeutics Ltd, Cambridge, United Kingdom., Vasiliauskaite L; Storm Therapeutics Ltd, Cambridge, United Kingdom., Saunders CJ; Storm Therapeutics Ltd, Cambridge, United Kingdom., Tsagkogeorga G; Storm Therapeutics Ltd, Cambridge, United Kingdom.; Milner Therapeutics Institute, University of Cambridge, Cambridge, United Kingdom., Azevedo A; Storm Therapeutics Ltd, Cambridge, United Kingdom., Obacz J; Storm Therapeutics Ltd, Cambridge, United Kingdom., Pilka ES; Evotec (UK) Ltd, Abingdon, United Kingdom., Carkill M; Charles River Laboratories, Portishead, United -Kingdom., MacPherson L; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia., Wainwright EN; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia., Liddicoat B; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia., Blyth BJ; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia., Albertella MR; Storm Therapeutics Ltd, Cambridge, United Kingdom., Rausch O; Storm Therapeutics Ltd, Cambridge, United Kingdom., Dawson MA; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia.; Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Victoria, Australia.; Centre for Cancer Research, University of Melbourne, Melbourne, -Victoria, Australia.

Publikováno v: Cancer discovery [Cancer Discov] 2023 Oct 05; Vol. 13 (10), pp. 2228-2247.

Pharmacological inhibition of METTL3 impacts specific haematopoietic lineages.

Autor: Sturgess K; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW, UK.; Department of Haematology, University of Cambridge, Cambridge, CB2 0AW, UK., Yankova E; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW, UK.; Department of Haematology, University of Cambridge, Cambridge, CB2 0AW, UK.; Milner Therapeutics Institute, University of Cambridge, Puddicombe Way, Cambridge, CB2 0AW, UK., Vijayabaskar MS; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW, UK.; Department of Haematology, University of Cambridge, Cambridge, CB2 0AW, UK., Isobe T; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW, UK.; Department of Haematology, University of Cambridge, Cambridge, CB2 0AW, UK., Rak J; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW, UK.; Department of Haematology, University of Cambridge, Cambridge, CB2 0AW, UK., Kucinski I; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW, UK.; Department of Haematology, University of Cambridge, Cambridge, CB2 0AW, UK., Barile M; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW, UK.; Department of Haematology, University of Cambridge, Cambridge, CB2 0AW, UK., Webster NA; Storm Therapeutics Ltd, Babraham Research Campus, Cambridge, CB22 3AT, UK., Eleftheriou M; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW, UK.; Department of Haematology, University of Cambridge, Cambridge, CB2 0AW, UK.; Milner Therapeutics Institute, University of Cambridge, Puddicombe Way, Cambridge, CB2 0AW, UK., Hannah R; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW, UK.; Department of Haematology, University of Cambridge, Cambridge, CB2 0AW, UK., Gozdecka M; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW, UK.; Department of Haematology, University of Cambridge, Cambridge, CB2 0AW, UK., Vassiliou G; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW, UK.; Department of Haematology, University of Cambridge, Cambridge, CB2 0AW, UK., Rausch O; Storm Therapeutics Ltd, Babraham Research Campus, Cambridge, CB22 3AT, UK., Wilson NK; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW, UK.; Department of Haematology, University of Cambridge, Cambridge, CB2 0AW, UK., Göttgens B; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW, UK. bg200@cam.ac.uk.; Department of Haematology, University of Cambridge, Cambridge, CB2 0AW, UK. bg200@cam.ac.uk., Tzelepis K; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW, UK. kt404@cam.ac.uk.; Department of Haematology, University of Cambridge, Cambridge, CB2 0AW, UK. kt404@cam.ac.uk.; Milner Therapeutics Institute, University of Cambridge, Puddicombe Way, Cambridge, CB2 0AW, UK. kt404@cam.ac.uk.; Experimental Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, UK. kt404@cam.ac.uk.

Publikováno v: Leukemia [Leukemia] 2023 Oct; Vol. 37 (10), pp. 2133-2137. Date of Electronic Publication: 2023 Jul 19.

Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia.

Autor: Yankova E; Milner Therapeutics Institute, University of Cambridge, Cambridge, UK.; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge, UK.; Storm Therapeutics Ltd, Cambridge, UK., Blackaby W; Storm Therapeutics Ltd, Cambridge, UK., Albertella M; Storm Therapeutics Ltd, Cambridge, UK., Rak J; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge, UK.; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK., De Braekeleer E; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge, UK.; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK., Tsagkogeorga G; Milner Therapeutics Institute, University of Cambridge, Cambridge, UK.; Storm Therapeutics Ltd, Cambridge, UK., Pilka ES; Evotec (UK) Ltd, Abingdon, UK., Aspris D; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge, UK.; The Center for the Study of Hematological Malignancies/Karaiskakio Foundation, Nicosia, Cyprus., Leggate D; Storm Therapeutics Ltd, Cambridge, UK., Hendrick AG; Storm Therapeutics Ltd, Cambridge, UK., Webster NA; Storm Therapeutics Ltd, Cambridge, UK., Andrews B; Storm Therapeutics Ltd, Cambridge, UK., Fosbeary R; Storm Therapeutics Ltd, Cambridge, UK., Guest P; Storm Therapeutics Ltd, Cambridge, UK., Irigoyen N; Division of Virology, Department of Pathology, University of Cambridge, Cambridge, UK., Eleftheriou M; Milner Therapeutics Institute, University of Cambridge, Cambridge, UK., Gozdecka M; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge, UK., Dias JML; MRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge, UK., Bannister AJ; The Gurdon Institute and Department of Pathology, University of Cambridge, Cambridge, UK., Vick B; Research Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Munich, Germany.; German Consortium for Translational Cancer Research (DKTK), Munich, Germany., Jeremias I; Research Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Munich, Germany.; German Consortium for Translational Cancer Research (DKTK), Munich, Germany.; Department of Pediatrics, Dr. von Hauner Children's Hospital, Ludwig Maximilians University München, Munich, Germany., Vassiliou GS; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge, UK.; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.; The Center for the Study of Hematological Malignancies/Karaiskakio Foundation, Nicosia, Cyprus., Rausch O; Storm Therapeutics Ltd, Cambridge, UK. oliver.rausch@stormtherapeutics.com., Tzelepis K; Milner Therapeutics Institute, University of Cambridge, Cambridge, UK. kt404@cam.ac.uk.; Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge, UK. kt404@cam.ac.uk.; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK. kt404@cam.ac.uk.; The Gurdon Institute and Department of Pathology, University of Cambridge, Cambridge, UK. kt404@cam.ac.uk., Kouzarides T; Milner Therapeutics Institute, University of Cambridge, Cambridge, UK. t.kouzarides@gurdon.cam.ac.uk.; The Gurdon Institute and Department of Pathology, University of Cambridge, Cambridge, UK. t.kouzarides@gurdon.cam.ac.uk.

Publikováno v: Nature [Nature] 2021 May; Vol. 593 (7860), pp. 597-601. Date of Electronic Publication: 2021 Apr 26.

Predicting genes associated with RNA methylation pathways using machine learning.

Autor: Tsagkogeorga G; STORM Therapeutics Ltd, Babraham Research Campus, Cambridge, UK. georgia.tsagkogeorga@stormtherapeutics.com.; Milner Therapeutics Institute, University of Cambridge, Puddicombe Way, Cambridge, UK. georgia.tsagkogeorga@stormtherapeutics.com., Santos-Rosa H; The Gurdon Institute, University of Cambridge, Tennis Court Road, Cambridge, UK., Alendar A; The Gurdon Institute, University of Cambridge, Tennis Court Road, Cambridge, UK., Leggate D; STORM Therapeutics Ltd, Babraham Research Campus, Cambridge, UK., Rausch O; STORM Therapeutics Ltd, Babraham Research Campus, Cambridge, UK., Kouzarides T; Milner Therapeutics Institute, University of Cambridge, Puddicombe Way, Cambridge, UK.; The Gurdon Institute, University of Cambridge, Tennis Court Road, Cambridge, UK., Weisser H; STORM Therapeutics Ltd, Babraham Research Campus, Cambridge, UK. hendrik.weisser@stormtherapeutics.com., Han N; Milner Therapeutics Institute, University of Cambridge, Puddicombe Way, Cambridge, UK. n.han@milner.cam.ac.uk.; Cambridge Centre for AI in Medicine, Department of Applied Mathematics and Theoretical Physics, University of Cambridge, Cambridge, UK. n.han@milner.cam.ac.uk.

Publikováno v: Communications biology [Commun Biol] 2022 Aug 25; Vol. 5 (1), pp. 868. Date of Electronic Publication: 2022 Aug 25.